Chloroquine (CQ) and hydroxychloroquine (HCQ) are well-known 4-aminoquinoline antimalarial agents. Scientific evidence also supports the use of CQ and HCQ in the treatment of cancer. Overall, preclinical studies support CQ and HCQ use in anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they are able to sensitise tumour cells to a variety of drugs, potentiating the therapeutic activity. Thus far, clinical results are mostly in favour of the repurposing of CQ.

Recent in vitro and animal studies have found the proton pump inhibitor (PPI) lansoprazole to be highly active against Mycobacterium tuberculosis. Omeprazole and pantoprazole have no activity. There is no evidence that, in clinical practice, lansoprazole can treat or prevent incident tuberculosis (TB) disease.

Original Source

Adverse drug reactions (ADRs) are a matter of great concern in drug research. This study focuses on drugs which have been banned or withdrawn, due to serious problem of adverse reactions. Our attempt is to develop insights through plotting of data on cumulative counts of ADR reports. These data have been sourced from www.vigiaccess.org. Our expectation is that once a drug is banned/withdrawn, its count of ADR reports should fall precipitously and remain there. Instead a variety of shapes is encountered.